The Chinese National Institute of Pharmaceutical R&D Co. Ltd. has described sulfonamide compounds acting as tyrosine-protein phosphatase non-receptor type 11 (PTPN11; PTP-2C; SHP-2) inhibitors reported to be useful for the treatment of diabetes, obesity, cancer, Noonan and LEOPARD syndromes.
Research at Enveric Biosciences Canada Inc. has led to the development of aminated psilocybin derivatives acting as 5-HT1A or 5-HT2A receptor modulators and reported to be useful for the treatment of psychiatric disorders.
Vifor Pharma Ltd. has identified solute carrier family 40 member 1 (SLC40A1; ferroportin) inhibitors reported to be useful for the treatment of iron metabolism disorders, among others.
Shionogi & Co. Ltd. has synthesized spiroheterocycle derivatives acting as 5-HT2A and 5-HT2C receptor antagonists and/or inverse agonists reported to be useful for the treatment of neurodegeneration.
Merck Sharp & Dohme Corp. have identified nicotinic α7 receptor positive allosteric modulators reported to be useful for the treatment of Alzheimer’s and Parkinson’s diseases, and schizophrenia.
Zeno Management Inc. researchers have prepared and tested azole compounds described as transcriptional enhancer factor (TEAD) inhibitors potentially useful for the treatment of autoimmune diseases, inflammation and cancer.
Benzimidazole carboxylic acids acting as glucagon-like peptide 1 receptor (GLP-1R) agonists have been reported in a Terns Pharmaceuticals Inc. patent as potentially useful for the treatment of diabetes, obesity and liver diseases.
Research at Incyte Corp. has led to the development of hetero-tricyclic compounds acting as GTPase KRAS (mutant) inhibitors and thus reported to be useful for the treatment of cancer, inflammatory and immunological disorders.
RSS